Shares of Evolent Health Inc (NYSE:EVH) have received an average rating of “Buy” from the fifteen research firms that are presently covering the firm, Marketbeat reports. Two investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. The average 12-month target price among brokerages that have covered the stock in the last year is $27.50.
A number of research firms recently commented on EVH. ValuEngine downgraded shares of Evolent Health from a “buy” rating to a “hold” rating in a report on Tuesday, January 29th. TheStreet downgraded shares of Evolent Health from a “c-” rating to a “d+” rating in a report on Friday, February 22nd. KeyCorp decreased their price objective on shares of Evolent Health from $32.00 to $20.00 and set an “overweight” rating on the stock in a report on Monday, March 4th. Cantor Fitzgerald reissued a “buy” rating and set a $37.00 price objective on shares of Evolent Health in a report on Monday, December 31st. Finally, Wells Fargo & Co decreased their price objective on shares of Evolent Health from $34.00 to $21.50 and set an “outperform” rating on the stock in a report on Wednesday, February 27th.
NYSE EVH traded down $0.10 during trading on Monday, reaching $13.51. The company’s stock had a trading volume of 15,350 shares, compared to its average volume of 1,212,000. The company has a debt-to-equity ratio of 0.19, a quick ratio of 1.81 and a current ratio of 1.81. The firm has a market cap of $1.13 billion, a PE ratio of -38.36 and a beta of 1.24. Evolent Health has a twelve month low of $12.09 and a twelve month high of $29.05.
Several hedge funds and other institutional investors have recently made changes to their positions in the business. Oppenheimer Asset Management Inc. increased its position in Evolent Health by 9.2% during the first quarter. Oppenheimer Asset Management Inc. now owns 169,973 shares of the technology company’s stock worth $2,138,000 after purchasing an additional 14,366 shares during the last quarter. Redmond Asset Management LLC boosted its stake in shares of Evolent Health by 2.3% in the first quarter. Redmond Asset Management LLC now owns 70,171 shares of the technology company’s stock valued at $883,000 after purchasing an additional 1,592 shares during the period. Pier Capital LLC boosted its stake in shares of Evolent Health by 99.3% in the first quarter. Pier Capital LLC now owns 667,999 shares of the technology company’s stock valued at $8,403,000 after purchasing an additional 332,820 shares during the period. Mercer Global Advisors Inc. ADV purchased a new position in shares of Evolent Health in the first quarter valued at $162,000. Finally, Trellus Management Company LLC purchased a new position in shares of Evolent Health in the first quarter valued at $315,000.
Evolent Health Company Profile
Evolent Health, Inc, through its subsidiary, Evolent Health LLC, provides health care delivery and payment solutions in the United States. The company operates as a managed services firm that supports health systems and physician organizations in migration toward value-based care and population health management.
Featured Story: What is a Market Correction?
Receive News & Ratings for Evolent Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health and related companies with MarketBeat.com's FREE daily email newsletter.